Invasive  ||| S:0 E:9 ||| JJ
mycoses ||| S:9 E:16 ||| NN
:  ||| S:16 E:18 ||| :
strategies  ||| S:18 E:29 ||| NNS
for  ||| S:29 E:33 ||| IN
effective  ||| S:33 E:43 ||| JJ
management  ||| S:43 E:54 ||| NN
Effective  ||| S:54 E:64 ||| NNP
management  ||| S:64 E:75 ||| NN
of  ||| S:75 E:78 ||| IN
invasive  ||| S:78 E:87 ||| JJ
fungal  ||| S:87 E:94 ||| JJ
infections  ||| S:94 E:105 ||| NNS
( ||| S:105 E:106 ||| -LRB-
IFIs ||| S:106 E:110 ||| NNP
)  ||| S:110 E:112 ||| -RRB-
depends  ||| S:112 E:120 ||| VBZ
on  ||| S:120 E:123 ||| IN
early  ||| S:123 E:129 ||| JJ
individualized  ||| S:129 E:144 ||| JJ
therapy  ||| S:144 E:152 ||| NN
that  ||| S:152 E:157 ||| IN
optimizes  ||| S:157 E:167 ||| JJ
efficacy  ||| S:167 E:176 ||| NN
and  ||| S:176 E:180 ||| CC
safety ||| S:180 E:186 ||| NN
.  ||| S:186 E:188 ||| .
Considering  ||| S:188 E:200 ||| VBG
the  ||| S:200 E:204 ||| DT
negative  ||| S:204 E:213 ||| JJ
consequences  ||| S:213 E:226 ||| NNS
of  ||| S:226 E:229 ||| IN
IFI ||| S:229 E:232 ||| NNP
,  ||| S:232 E:234 ||| ,
for  ||| S:234 E:238 ||| IN
some  ||| S:238 E:243 ||| DT
high-risk  ||| S:243 E:253 ||| JJ
patients  ||| S:253 E:262 ||| NNS
the  ||| S:262 E:266 ||| DT
potential  ||| S:266 E:276 ||| JJ
benefits  ||| S:276 E:285 ||| NNS
of  ||| S:285 E:288 ||| IN
prophylactic  ||| S:288 E:301 ||| JJ
therapy  ||| S:301 E:309 ||| NN
may  ||| S:309 E:313 ||| MD
outweigh  ||| S:313 E:322 ||| VB
the  ||| S:322 E:326 ||| DT
risks ||| S:326 E:331 ||| NNS
.  ||| S:331 E:333 ||| .
When  ||| S:333 E:338 ||| WRB
using  ||| S:338 E:344 ||| VBG
a  ||| S:344 E:346 ||| DT
prophylactic ||| S:346 E:358 ||| NN
,  ||| S:358 E:360 ||| ,
empiric ||| S:360 E:367 ||| NN
,  ||| S:367 E:369 ||| ,
or  ||| S:369 E:372 ||| CC
preemptive  ||| S:372 E:383 ||| JJ
therapeutic  ||| S:383 E:395 ||| JJ
approach ||| S:395 E:403 ||| NN
,  ||| S:403 E:405 ||| ,
clinicians  ||| S:405 E:416 ||| NNS
must  ||| S:416 E:421 ||| MD
take  ||| S:421 E:426 ||| VB
into  ||| S:426 E:431 ||| IN
account  ||| S:431 E:439 ||| NN
the  ||| S:439 E:443 ||| DT
local  ||| S:443 E:449 ||| JJ
epidemiology ||| S:449 E:461 ||| NN
,  ||| S:461 E:463 ||| ,
spectrum  ||| S:463 E:472 ||| NN
of  ||| S:472 E:475 ||| IN
activity ||| S:475 E:483 ||| NN
,  ||| S:483 E:485 ||| ,
pharmacokinetic  ||| S:485 E:501 ||| NN
and  ||| S:501 E:505 ||| CC
pharmacodynamic  ||| S:505 E:521 ||| JJ
parameters ||| S:521 E:531 ||| NNS
,  ||| S:531 E:533 ||| ,
and  ||| S:533 E:537 ||| CC
safety  ||| S:537 E:544 ||| NN
profile  ||| S:544 E:552 ||| NN
of  ||| S:552 E:555 ||| IN
different  ||| S:555 E:565 ||| JJ
antifungal  ||| S:565 E:576 ||| JJ
agents ||| S:576 E:582 ||| NNS
,  ||| S:582 E:584 ||| ,
together  ||| S:584 E:593 ||| RB
with  ||| S:593 E:598 ||| IN
unique  ||| S:598 E:605 ||| JJ
host-related  ||| S:605 E:618 ||| JJ
factors  ||| S:618 E:626 ||| NNS
that  ||| S:626 E:631 ||| WDT
may  ||| S:631 E:635 ||| MD
affect  ||| S:635 E:642 ||| VB
antifungal  ||| S:642 E:653 ||| JJ
efficacy  ||| S:653 E:662 ||| NN
or  ||| S:662 E:665 ||| CC
safety ||| S:665 E:671 ||| NN
.  ||| S:671 E:673 ||| .
Therapeutic  ||| S:673 E:685 ||| JJ
drug  ||| S:685 E:690 ||| NN
monitoring  ||| S:690 E:701 ||| NN
is  ||| S:701 E:704 ||| VBZ
increasingly  ||| S:704 E:717 ||| RB
recognized  ||| S:717 E:728 ||| VBN
as  ||| S:728 E:731 ||| IN
important  ||| S:731 E:741 ||| JJ
or  ||| S:741 E:744 ||| CC
necessary  ||| S:744 E:754 ||| JJ
when  ||| S:754 E:759 ||| WRB
employing  ||| S:759 E:769 ||| VBG
lipophilic  ||| S:769 E:780 ||| JJ
triazoles  ||| S:780 E:790 ||| NNS
( ||| S:790 E:791 ||| -LRB-
itraconazole ||| S:791 E:803 ||| UH
,  ||| S:803 E:805 ||| ,
voriconazole ||| S:805 E:817 ||| NN
,  ||| S:817 E:819 ||| ,
posaconazole ||| S:819 E:831 ||| CD
)  ||| S:831 E:833 ||| -RRB-
or  ||| S:833 E:836 ||| CC
flucytosine ||| S:836 E:847 ||| NN
.  ||| S:847 E:849 ||| .
Because  ||| S:849 E:857 ||| IN
early  ||| S:857 E:863 ||| JJ
diagnostics  ||| S:863 E:875 ||| NNS
remain  ||| S:875 E:882 ||| VBP
limited  ||| S:882 E:890 ||| VBN
for  ||| S:890 E:894 ||| IN
uncommon ||| S:894 E:902 ||| JJ
,  ||| S:902 E:904 ||| ,
yet  ||| S:904 E:908 ||| RB
emerging  ||| S:908 E:917 ||| VBG
opportunistic  ||| S:917 E:931 ||| JJ
molds  ||| S:931 E:937 ||| NNS
( ||| S:937 E:938 ||| -LRB-
e.g. ||| S:938 E:942 ||| NNP
,  ||| S:942 E:944 ||| ,
Mucorales ||| S:944 E:953 ||| NNP
) ||| S:953 E:954 ||| -RRB-
,  ||| S:954 E:956 ||| ,
and  ||| S:956 E:960 ||| CC
treatment  ||| S:960 E:970 ||| NN
delay  ||| S:970 E:976 ||| NN
is  ||| S:976 E:979 ||| VBZ
associated  ||| S:979 E:990 ||| VBN
with  ||| S:990 E:995 ||| IN
increased  ||| S:995 E:1005 ||| JJ
mortality ||| S:1005 E:1014 ||| NN
,  ||| S:1014 E:1016 ||| ,
early  ||| S:1016 E:1022 ||| RB
effective  ||| S:1022 E:1032 ||| JJ
management  ||| S:1032 E:1043 ||| NN
often  ||| S:1043 E:1049 ||| RB
depends  ||| S:1049 E:1057 ||| VBZ
on  ||| S:1057 E:1060 ||| IN
a  ||| S:1060 E:1062 ||| DT
high  ||| S:1062 E:1067 ||| JJ
index  ||| S:1067 E:1073 ||| NN
of  ||| S:1073 E:1076 ||| IN
suspicion ||| S:1076 E:1085 ||| NN
,  ||| S:1085 E:1087 ||| ,
taking  ||| S:1087 E:1094 ||| VBG
into  ||| S:1094 E:1099 ||| IN
account  ||| S:1099 E:1107 ||| NN
predisposing  ||| S:1107 E:1120 ||| NN
factors ||| S:1120 E:1127 ||| NNS
,  ||| S:1127 E:1129 ||| ,
host  ||| S:1129 E:1134 ||| FW
cues  ||| S:1134 E:1139 ||| FW
favoring  ||| S:1139 E:1148 ||| FW
mucormycosis ||| S:1148 E:1160 ||| FW
,  ||| S:1160 E:1162 ||| ,
and  ||| S:1162 E:1166 ||| CC
local  ||| S:1166 E:1172 ||| JJ
epidemiology ||| S:1172 E:1184 ||| NN
.  ||| S:1184 E:1186 ||| .
Antifungal  ||| S:1186 E:1197 ||| JJ
options  ||| S:1197 E:1205 ||| NNS
for  ||| S:1205 E:1209 ||| IN
mucormycosis  ||| S:1209 E:1222 ||| NNS
are  ||| S:1222 E:1226 ||| VBP
limited ||| S:1226 E:1233 ||| VBN
,  ||| S:1233 E:1235 ||| ,
and  ||| S:1235 E:1239 ||| CC
optimal  ||| S:1239 E:1247 ||| JJ
management  ||| S:1247 E:1258 ||| NN
depends  ||| S:1258 E:1266 ||| VBZ
on  ||| S:1266 E:1269 ||| IN
a  ||| S:1269 E:1271 ||| DT
multimodal  ||| S:1271 E:1282 ||| JJ
approach  ||| S:1282 E:1291 ||| NN
that  ||| S:1291 E:1296 ||| WDT
includes  ||| S:1296 E:1305 ||| VBZ
early  ||| S:1305 E:1311 ||| JJ
diagnosis ||| S:1311 E:1320 ||| NN
/ ||| S:1320 E:1321 ||| CD
clinical  ||| S:1321 E:1330 ||| JJ
suspicion ||| S:1330 E:1339 ||| NN
,  ||| S:1339 E:1341 ||| ,
correction  ||| S:1341 E:1352 ||| NN
of  ||| S:1352 E:1355 ||| IN
underlying  ||| S:1355 E:1366 ||| VBG
predisposing  ||| S:1366 E:1379 ||| JJ
factors ||| S:1379 E:1386 ||| NNS
,  ||| S:1386 E:1388 ||| ,
radical  ||| S:1388 E:1396 ||| JJ
debridement  ||| S:1396 E:1408 ||| NN
of  ||| S:1408 E:1411 ||| IN
affected  ||| S:1411 E:1420 ||| JJ
tissues ||| S:1420 E:1427 ||| NNS
,  ||| S:1427 E:1429 ||| ,
and  ||| S:1429 E:1433 ||| CC
extended  ||| S:1433 E:1442 ||| VBD
antifungal  ||| S:1442 E:1453 ||| JJ
therapy ||| S:1453 E:1460 ||| NN
.  ||| S:1460 E:1462 ||| .
This  ||| S:1462 E:1467 ||| DT
article  ||| S:1467 E:1475 ||| NN
discusses  ||| S:1475 E:1485 ||| NN
strategies  ||| S:1485 E:1496 ||| NNS
for  ||| S:1496 E:1500 ||| IN
the  ||| S:1500 E:1504 ||| DT
effective  ||| S:1504 E:1514 ||| JJ
management  ||| S:1514 E:1525 ||| NN
of  ||| S:1525 E:1528 ||| IN
invasive  ||| S:1528 E:1537 ||| JJ
mycoses ||| S:1537 E:1544 ||| NN
,  ||| S:1544 E:1546 ||| ,
with  ||| S:1546 E:1551 ||| IN
a  ||| S:1551 E:1553 ||| DT
particular  ||| S:1553 E:1564 ||| JJ
focus  ||| S:1564 E:1570 ||| NN
on  ||| S:1570 E:1573 ||| IN
antifungal  ||| S:1573 E:1584 ||| JJ
hepatotoxicity ||| S:1584 E:1598 ||| NN
.  ||| S:1598 E:1600 ||| .
